SERVICES Online Inquiry

TAC Generation & Optimization

Creative Biolabs is a leading global company that is dedicated to helping our worldwide customers shorten the discovery and development time in T Cell Antigen Connector (TAC) engineered T cell therapy. We offer a broad and integrated portfolio of laboratory and manufacturing services, especially for TAC engineered T cell design, construct, validation, and function assessment. Particularly, the generation and optimization of TAC play an important role in TAC T cell therapy development, which can be crucial to your projects.

T-cell receptor (TCR), is a molecule that often exists on the T cells surface, that is associated with many functions in immune responses. Decades of studies on TCR reveal that it can recognize antigen fragments submitted by major histocompatibility complex (MHC) molecules. Usually, the binding between TCR and antigen peptides is not very close with a relatively low affinity. In this condition, many novel technologies have been developed for improving the ability of T cell receptors to recognize and attack specific antigenic cell antigens utilizing genetic modification, such as CAR-T (Chimeric Antibody Receptor Engineered T Cell) and affinity-enhanced TCR. These two technologies have proven to be highly effective strategies for disease therapy, but the clinical data also show that both technologies have their disadvantages, including potentially lethal, toxicities as well as poor treatment effect.

To overcome these limitations, Creative Biolabs offers a novel strategy to redirect T cells in a TCR-dependent, MHC-independent manner to locate and kill tumor cells. This TAC technology is designed as an alternative receptor, which operates through the native TCR with enhanced anti-tumor efficacy and decreased off-tumor toxicity. The TAC Engineered T Cell Development Services including TAC Biomarker Identification & Selection, TAC Generation & Optimization, TAC Design & Construction, and TAC In Vitro Assay. Creative Biolabs provides solutions for our worldwide customers with a wide range of services on TAC development that can shorten the time-to-clinic and save your budget for drug development.

Strategies to enhance adoptive T cell therapy by targeting immune checkpoint pathways.Fig.1 Strategies to enhance adoptive T cell therapy by targeting immune checkpoint pathways. (Mardiana, 2019)

Creative Biolabs offers a series of TAC Generation & Optimization services which are part of our integrated portfolio of TAC engineered T cell development services. With experienced teams of scientists, researchers, and technicians, we provide a fast turnaround, high-quality data at competitive prices for worldwide customers. Our clients have direct access to our staff and prompt feedback to their inquiries. If you are interested in our services, please contact us for more details.

Reference

  1. Mardiana, S.; et al. Supercharging adoptive T cell therapy to overcome solid tumor-induced immunosuppression. Science translational medicine. 2019, 11(495).

For Research Use Only


Tel:
Fax:

Tel: